Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded at StockNews.com

StockNews.com upgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a sell rating to a hold rating in a research report sent to investors on Wednesday.

Separately, HC Wainwright reissued a “neutral” rating on shares of Oramed Pharmaceuticals in a report on Monday, September 9th.

Oramed Pharmaceuticals Price Performance

ORMP opened at $2.37 on Wednesday. The company has a 50 day simple moving average of $2.38 and a two-hundred day simple moving average of $2.39. The firm has a market cap of $95.54 million, a P/E ratio of 21.55 and a beta of 1.70. Oramed Pharmaceuticals has a 1-year low of $2.00 and a 1-year high of $3.67.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ORMP. Dimensional Fund Advisors LP boosted its holdings in shares of Oramed Pharmaceuticals by 52.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after purchasing an additional 10,774 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Oramed Pharmaceuticals by 89.0% during the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after buying an additional 108,700 shares during the last quarter. XTX Topco Ltd purchased a new position in Oramed Pharmaceuticals during the 2nd quarter valued at approximately $40,000. Murchinson Ltd. increased its stake in Oramed Pharmaceuticals by 23.2% in the 2nd quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock worth $4,369,000 after acquiring an additional 320,495 shares during the last quarter. Finally, BML Capital Management LLC increased its stake in Oramed Pharmaceuticals by 62.1% in the 3rd quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock worth $5,334,000 after acquiring an additional 837,153 shares during the last quarter. Institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.